What is the Cognition Therapeutics Inc. stock price forecast?

Cognition Therapeutics Inc. is currently trading at $1.21. View real-time AI analysis on Alpha Lenz.

What is Cognition Therapeutics Inc. insider trading activity?

View the latest insider trading data for Cognition Therapeutics Inc. on Alpha Lenz.

What is Cognition Therapeutics Inc.'s P/E ratio?

Cognition Therapeutics Inc.'s P/E ratio is -3.7.

Cognition Therapeutics Inc.

NASDAQ · CGTX

$1.21+0.01(+0.83%)Pre-market

Ask about Cognition Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Cognition Therapeutics Inc. trades at a P/E of -3.7 (undervalued) with modest ROE of -88.6%.”

Ask for details →

Company Overview

Cognition Therapeutics Inc. is a biopharmaceutical company dedicated to the research and development of novel therapeutics aimed at treating neurodegenerative diseases. The company's primary focus is on Alzheimer's disease, where it seeks to address underlying causes related to synaptic mechanisms. The company leverages its proprietary platform to identify and develop small molecule therapies that can potentially modulate brain cell receptors to restore and protect cognitive function. Cognition Therapeutics operates within the healthcare and life sciences sectors, primarily impacting areas related to neurological disorders. With its robust pipeline of investigational drugs, the company plays a significant role in the biotech segment, concentrating on high unmet medical needs. Cognition Therapeutics' work aims to contribute to medical advancements by providing new hope and alternatives for patients suffering from debilitating brain diseases.

CEOMs. Lisa Ricciardi

Websitehttps://www.cogrx.com

SectorHealthcare

IndustryBiotechnology

Employees25

Company Statistics

FY 2025

Profile

$88.05MMarket Cap

$0.00Revenue

0.00Shares Out

25Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-3.75P/E

2.57P/B

N/AEV/Sales

-2.23EV/EBITDA

-3.58P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-59.75%ROA

-88.60%ROE

-59.71%ROIC

Financial Health

$36.81MCash & Cash Equivalents

$-22.69MNet Debt

41.20%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Cognition Therapeutics Inc. trades at a P/E of -3.7 (undervalued) with modest ROE of -88.6%.”

Ask for details →

Frequently Asked Questions

Cognition Therapeutics Inc. (ticker: CGTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 25 employees. Market cap is $88M.

The current price is $1.21 with a P/E ratio of -3.75x and P/B of 2.57x.

ROE is -88.60%.